News
CLLS
2.470
+0.41%
0.010
Weekly Report: what happened at CLLS last week (0408-0412)?
Weekly Report · 3d ago
Cellectis Unveils Gene Therapy Breakthrough
TipRanks · 04/11 08:38
Cellectis Publishes Novel Intronic Gene Editing Approach For Inborn Metabolic Diseases By Edited HSPCs
Benzinga · 04/10 20:31
Cellectis Unveils Breakthrough Gene-Editing Innovations
TipRanks · 04/08 20:57
Cellectis Announces Two Poster Presentations On Novel TALEN Editing Process For Gene Correction And Gene Insertion In HSPCs At The ASGCT Annual Meeting
Preliminary data exploring novel TALEN® editing process in hematopoietic stem and progenitor cells will be presented at the American Society of Gene and Cell Therapy's 27th Annual Meeting in 2024. Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies.
Benzinga · 04/08 20:36
Weekly Report: what happened at CLLS last week (0401-0405)?
Weekly Report · 04/08 09:41
Monthly information on share capital and company voting rights
Barchart · 04/04 15:30
Weekly Report: what happened at CLLS last week (0325-0329)?
Weekly Report · 04/01 09:41
Weekly Report: what happened at CLLS last week (0318-0322)?
Weekly Report · 03/25 09:42
Cibus Inc <CBUS.OQ> expected to post a loss of $1.43 a share - Earnings Preview
Cibus Inc expected to post a loss of $1.43 a share - Earnings Preview. The company is expected to show a rise in quarterly revenue when it reports results on March 21 for the period ending December 31 2023. Cibus expected to report a 815.5% increase in revenue.
Reuters · 03/19 21:23
Weekly Report: what happened at CLLS last week (0311-0315)?
Weekly Report · 03/18 09:41
Earnings week ahead: FedEx, Nike, XPeng, Tencent, General Mills and more
Earnings week of March 18 to 22 will feature major quarterly updates from FedEx, XPeng, Tencent, General Mills and more. The week will also feature important announcements from Nike, Lululemon Athletica and Chewy. Technology companies are also in focus with earnings results from Micron, Accenture and others.
Seeking Alpha · 03/17 12:20
Weekly Report: what happened at CLLS last week (0304-0308)?
Weekly Report · 03/11 09:40
Monthly information on share capital and company voting rights
Barchart · 03/04 15:30
Weekly Report: what happened at CLLS last week (0226-0301)?
Weekly Report · 03/04 09:41
Cibus Inc <CBUS.OQ> expected to post a loss of $1.43 a share - Earnings Preview
Cibus Inc expected to post a loss of $1.43 a share - Earnings Preview. The company is expected to show a rise in quarterly revenue when it reports results on March 1 for the period ending December 31 2023.
Reuters · 02/28 21:03
SMXT, ANVS and IFBD among pre-market losers
On the Move SMXT, ANVS and IFBD among pre-market losers. Oragenics OGEN -45% after pricing $2.1M stock offering. Palatin Technologies -37% announces results of dry eye disease clinical trial. Novavax -19% reports fourth quarter and full year 2023 results.
Seeking Alpha · 02/28 13:25
Weekly Report: what happened at CLLS last week (0219-0223)?
Weekly Report · 02/26 09:45
Weekly Report: what happened at CLLS last week (0212-0216)?
Weekly Report · 02/19 09:45
Cellectis: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 02/15 02:03
More
Webull provides a variety of real-time CLLS stock news. You can receive the latest news about Cellectis through multiple platforms. This information may help you make smarter investment decisions.
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.